Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation
Cancer Communications · 2024-09 · 44 (9) · 1018-1041
DOI: 10.1002/cac2.12595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 19.07.2024. Verfasst von Hailing Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cytidine. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State Key Project on Infection Disease of China, Tongji Hospital (HUST) Foundation for Excellent Young Scientist, National Basic Research Program of China.
Abstract (Originalsprache)
Background
N4‐acetylcytidine (ac4C) represents a novel messenger RNA (mRNA) modification, and its associated acetyltransferase N‐acetyltransferase 10 (NAT10) plays a crucial role in the initiation and progression of tumors by regulating mRNA functionality. However, its role in hepatocellular carcinoma (HCC) development and prognosis is largely unknown. This study aimed to elucidate the role of NAT10‐mediated ac4C in HCC progression and provide a promising therapeutic approach.
Methods
The ac4C levels were evaluated by dot blot and ultra‐performance liquid chromatography‐tandem mass spectrometry with harvested HCC tissues. The expression of NAT10 was investigated using quantitative real‐time polymerase chain reaction, western blotting, and immunohistochemical staining across 91 cohorts of HCC patients. To explore the underlying mechanisms of NAT10‐ac4C in HCC, we employed a comprehensive approach integrating acetylated RNA immunoprecipitation and sequencing, RNA sequencing and ribosome profiling analyses, along with RNA immunoprecipitation, RNA pull‐down, mass spectrometry, and site‐specific mutation analyses. The drug affinity responsive targets stability, cellular thermal shift assay, and surface plasmon resonance assays were performed to assess the specific binding of NAT10 and Panobinostat. Furthermore, the efficacy of targeting NAT10‐ac4C for HCC treatment was elucidated through in vitro experiments using HCC cells and in vivo HCC mouse models.
Results
Our investigation revealed a significant increase in both the ac4C RNA level and NAT10 expression in HCC. Notably, elevated NAT10 expression was associated with poor outcomes in HCC patients. Functionally, silencing NAT10 suppressed HCC proliferation and metastasis in vitro and in vivo. Mechanistically, NAT10 stimulates the ac4C modification within the coding sequence (CDS) of high mobility group protein B2 (HMGB2), which subsequently enhances HMGB2 translation by facilitating eukaryotic elongation factor 2 (eEF2) binding to the ac4C sites on HMGB2 mRNA's CDS. Additionally, high‐throughput compound library screening revealed Panobinostat as a potent inhibitor of NAT10‐mediated ac4C modification. This inhibition significantly attenuated HCC growth and metastasis in both in vitro experiments using HCC cells and in vivo HCC mouse models.
Conclusions
Our study identified a novel oncogenic epi‐transcriptome axis involving NAT10‐ac4C/eEF2‐HMGB2, which plays a pivotal role in regulating HCC growth and metastasis. The drug Panobinostat validates the therapeutic potential of targeting this axis for HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
- Hubei Key Laboratory of Hepato‑Pancreatic‑Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
- Department of Hepatopancreatobiliary Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.
- Department of Hepatobiliary Pancreatic Tumor Center, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Chongqing, P. R. China.
- Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, Hubei, P. R. China.
- Department of Hepatobiliary Surgery, Key Laboratory of Hepatobiliary and Pancreatic Diseases of Shanxi Province (Preparatory), Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University, Taiy…
ORCID-Profile: Hailing Liu, Shiwei Yue, Hongfei Su, Huifang Liang, Bixiang Zhang
Förderung
- State Key Project on Infection Disease of China
- Tongji Hospital (HUST) Foundation for Excellent Young Scientist
- National Basic Research Program of China
- Knowledge Innovation Program of Wuhan-Shuguang Project
- the first level of the public health youth top talent project of Hubei province
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Liu, H., Xu, L., Yue, S., Su, H., Chen, X., Liu, Q., Li, H., Liang, H., Chen, X., He, J., Ding, Z., & Zhang, B. (2024). Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation. Cancer Communications, 44(9), 1018-1041. https://doi.org/10.1002/cac2.12595
Vancouver
Liu H, Xu L, Yue S, Su H, Chen X, Liu Q, et al. Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation. Cancer Communications. 2024;44(9):1018-1041. doi:10.1002/cac2.12595
BibTeX
@article{Liu2024,
author = {Liu, Hailing and Xu, Lei and Yue, Shiwei and Su, Hongfei and Chen, Xing and Liu, Qiumeng and Li, Hui and Liang, Huifang and Chen, Xiaoping and He, Jiefeng and Ding, Zeyang and Zhang, Bixiang},
title = {Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {9},
pages = {1018--1041},
doi = {10.1002/cac2.12595}
}
EUVIMED